600436.SH
片仔癀
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 123.76
−0.27%Sep 3, 2026, 19:26 UTC
Pien Tze Huang's liver disease drug revenue fell about 19% year-on-year to 2.348 billion yuan in the first half of 2026.
Source:Sep 3, 2026, 19:26 UTC
Pien Tze Huang reported second-quarter 2026 revenue of 1.832 billion yuan, down 18.12% year-on-year, and net profit attributable to shareholders of 349 million yuan, down 21.02%.
Source:Aug 28, 2026, 09:18 UTC
Pien Tze Huang proposed a cash dividend of 10.7 yuan per 10 shares, totaling 646 million yuan.
Aug 28, 2026, 09:18 UTC
Pien Tze Huang announced its first-half 2026 results: revenue of 4.573 billion yuan, down 14.98% year-on-year; net profit attributable to shareholders of 1.093 billion yuan, down 24.22% year-on-year; non-GAAP net profit of 1.055 billion yuan, down 27.41% year-on-year.
Jul 29, 2026, 10:10 UTC
Pian Zai Huang director and general manager Huang Jinming resigned on July 29, 2026 due to reaching the statutory retirement age, and will no longer hold any position in the company or its subsidiaries after leaving.
Source: